Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.
Constitutive activation of the mechano-sensor and transcription factor Yes-associated protein (YAP) is key to metastasis and epithelial-mesenchymal transition of triple-negative breast cancer, researchers from the Institute of Cancer Research, London, report.
Neuronal hypersensitivity specialist NeRRe Therapeutics has closed an oversubscribed Series B financing round led by Fountain Healthcare Partners.
The Innovative Medicines Initiative is pushing clinical development of a novel compound against Gram-negative bugs that cause urinary tract and intra-abdominal infections. Backed by IMI, Aicuris is launching a clinical programme for an antibiotic.
The London-based immunotherapy specialist Tiziana Life Sciences bagged the license for the human anti-interleukin 6 receptor antagonist NI-1201 from Swiss Novimmune.
French Sanofi is set to become a global market leader in the non-prescription market by acquiring Boehringer Ingelheims consumer healthcare (CHC) business in exchange for Sanofis animal health arm Merial.
Which European Biotechnology news stories topped the charts this year? The European Biotechnology team delved into archives and analysed the click statistics. And here they are: the most wanted news stories of 2016!
Contaminated blood can transmit prion disease even if the donor does not yet show any symptoms. A new blood test could make the blood supply safer. Two reports show it can correctly diagnose Variant Creutzfeldt-Jakob disease – with 100% certainty.
Electronic submission systems of the Innovative Medicines Initiative (IMI) will open for biotech companies and research groups on 4 January 2017 to apply for collaborative projects with pharma partners under the IMI scheme.
Indigo Diabetes NV has been spun-off from University of Ghent and international research institute imec with a series A financing of €7m. The companys needle-free glucose sensor addresses a €12bn market.